Tags

Type your tag names separated by a space and hit enter

Vitamin K Supplementation in Chronic Kidney Disease Patients: Where is the Evidence?
Curr Vasc Pharmacol. 2022; 20(2):121-126.CV

Abstract

Vascular calcification (VC) is highly prevalent in Chronic Kidney Disease (CKD) patients, progresses gradually with deterioration of kidney function and is a strong, independent predictor of cardiovascular (CV) mortality. Matrix Gla Protein (MGP), the most potent inhibitor of VC, requires vitamin K as a co-factor to become biologically active. Accumulating epidemiological data have associated vitamin K depletion with VC progression and CV outcomes. CKD patients are characterized by poor vitamin K status and at the same time, pronounced CV calcification. In early and advanced CKD, including end-stage kidney disease, exogenous supplementation of vitamin K (especially with menaquinone 7, its most bioavailable form) might decrease the inactive form of MGP (dephosphorylated, uncarboxylated MGP) and probably retard the progression or even reverse VC. Here, we focus and discuss the interventional human studies of vitamin K supplementation in CKD patients and suggest future directions in this area of interest.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Roumeliotis S
Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Liakopoulos V
Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Schurgers LJ
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University Medical Centre, 6200 MD Maastricht, The Netherlands.

MeSH

Dietary SupplementsFemaleHumansMaleRenal DialysisRenal Insufficiency, ChronicVascular CalcificationVitamin KVitamin K Deficiency

Pub Type(s)

Journal Article

Language

eng

PubMed ID

35139790

Citation

Roumeliotis, Stefanos, et al. "Vitamin K Supplementation in Chronic Kidney Disease Patients: Where Is the Evidence?" Current Vascular Pharmacology, vol. 20, no. 2, 2022, pp. 121-126.
Roumeliotis S, Liakopoulos V, Schurgers LJ. Vitamin K Supplementation in Chronic Kidney Disease Patients: Where is the Evidence? Curr Vasc Pharmacol. 2022;20(2):121-126.
Roumeliotis, S., Liakopoulos, V., & Schurgers, L. J. (2022). Vitamin K Supplementation in Chronic Kidney Disease Patients: Where is the Evidence? Current Vascular Pharmacology, 20(2), 121-126. https://doi.org/10.2174/1570161120666220209145341
Roumeliotis S, Liakopoulos V, Schurgers LJ. Vitamin K Supplementation in Chronic Kidney Disease Patients: Where Is the Evidence. Curr Vasc Pharmacol. 2022;20(2):121-126. PubMed PMID: 35139790.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Vitamin K Supplementation in Chronic Kidney Disease Patients: Where is the Evidence? AU - Roumeliotis,Stefanos, AU - Liakopoulos,Vassilios, AU - Schurgers,Leon J, PY - 2021/11/08/received PY - 2021/12/21/revised PY - 2021/12/23/accepted PY - 2022/2/11/pubmed PY - 2022/5/18/medline PY - 2022/2/10/entrez KW - Chronic kidney disease KW - dephosphorylated uncarboxylated MGP KW - end stage kidney disease KW - matrix gla protein KW - vascular calcification KW - vitamin K2 SP - 121 EP - 126 JF - Current vascular pharmacology JO - Curr Vasc Pharmacol VL - 20 IS - 2 N2 - Vascular calcification (VC) is highly prevalent in Chronic Kidney Disease (CKD) patients, progresses gradually with deterioration of kidney function and is a strong, independent predictor of cardiovascular (CV) mortality. Matrix Gla Protein (MGP), the most potent inhibitor of VC, requires vitamin K as a co-factor to become biologically active. Accumulating epidemiological data have associated vitamin K depletion with VC progression and CV outcomes. CKD patients are characterized by poor vitamin K status and at the same time, pronounced CV calcification. In early and advanced CKD, including end-stage kidney disease, exogenous supplementation of vitamin K (especially with menaquinone 7, its most bioavailable form) might decrease the inactive form of MGP (dephosphorylated, uncarboxylated MGP) and probably retard the progression or even reverse VC. Here, we focus and discuss the interventional human studies of vitamin K supplementation in CKD patients and suggest future directions in this area of interest. SN - 1875-6212 UR - https://www.unboundmedicine.com/medline/citation/35139790/Vitamin_K_Supplementation_in_Chronic_Kidney_Disease_Patients:_Where_is_the_Evidence DB - PRIME DP - Unbound Medicine ER -